Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Tesla, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Tesla, Inc. trades at $361.32 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 163.3× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| KYMR | TSLA | |
|---|---|---|
Market Cap | $8.88B | $1.45T |
Volume | 1,028,790 | 30,868,569 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $489.88 |
52-Week Low | $55.80 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $8.27B | $1.42T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $375.20, down 0.75% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The stock faces fundamental headwinds with a high P/E ratio of 347.44 and declining profit margins, though it has beaten earnings estimates in two of the last three quarters. Recent news highlights regulatory approval for its driver-assistance software in Europe and a strategic pivot toward robotics and AI.
The outlook remains bifurcated: long-term growth potential in autonomy and energy storage offers upside, but near-term risks include intense EV competition, earnings volatility, and rich valuations. Analyst consensus is a Buy with a $441.36 price target, yet investor sentiment is cautious due to delivery misses and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
